Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.60 |
| ▸ | HTR1A | P08908 | 3/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.60 |
| ▸ | DRD1 | P21728 | 3/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.60 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxomemazine SCHEMBL423634 | 1.00 | LMNA (0.60) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Oxomemazine SCHEMBL4420096 | 0.98 | LMNA (0.58) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL22882778 | 0.78 | CHRM2 (0.55) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL7344181 | 0.78 | RXFP1 (0.42) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Oxomemazine SCHEMBL28086314 | 0.76 | CYP2D6 (0.60) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Trimipramine SCHEMBL117756 | 0.75 | SLC6A4 (1.00) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Trimipramine SCHEMBL5494378 | 0.75 | SLC6A4 (1.00) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Methylpromazine SCHEMBL18993 | 0.75 | CHRM2 (1.00) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| Trimipramine SCHEMBL35144 | 0.75 | SLC6A4 (1.00) | LMNACHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL12265313 | 0.75 | CYP2D6 (0.63) | LMNACHRM2HTR1AADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119652760-A | Intelligent arrangement method for service function chain of user experience perception | 中国人民解放军国防科技大学 | 2025-03-18 | — | — | CN | claimed |
| US-20260015671-A1 | METHOD FOR DETECTING LUNG CANCER | GENOMICTREE INC (KR) | 2026-01-15 | — | — | US | disclosed |
| EP-4647071-A1 | MITOCHONDRIAL COMPLEX I MODULATOR FOR USE IN THE TREATMENT OF ARTHRITIS | Istesso Therapeutics Limited (GB) | 2025-11-12 | — | — | EP | disclosed |
| CN-119652760-A | Intelligent arrangement method for service function chain of user experience perception | 中国人民解放军国防科技大学 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024233957-A2 | COMPOSITIONS AND METHODS TO PREVENT, INHIBIT OR TREAT NEURODEGENERATIVE DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4431090-A1 | SOLFONAMIDES ACTING AS MITOCHONDRIAL COMPLEX I MODULATOR COMPOUNDS | Istesso 1 Limited (GB) | 2024-09-18 | — | — | EP | disclosed |
| EP-4164666-A2 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS USING HARRYFLINTIA ACETISPORA | Evelo Biosciences, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2023034232-A1 | A SMALL MOLECULE THERAPEUTIC FOR FRIEDREICH'S ATAXIA AND TAUOPATHY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-3990434-A1 | COMPOUNDS HAVING ANTIMALARIAL ACTIVITY | Nanyang Technological University (SG) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022031859-A2 | METHYLMALONIC ACID AND METABOLISM THEREOF IS A CANCER BIOMARKER AND TARGET | CORNELL UNIVERSITY (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015671-A1 | METHOD FOR DETECTING LUNG CANCER | DSC1, DSG1, TET1 | LMNA 4323/4885CHRM2 598/4885HTR1A 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.